Israeli biotech receives $30M: Lutris Pharma stated the funding should help it take a look at a topical gel that aims to lower EGFRi-induced rashes caused by specific cancer drugs. We have been excited about the chance to collaborate with BioAge to share Lilly’s know-how in incretins, and u